Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market: A Significant Driver Propelling The Nontuberculous Mycobacterial Infection Market In 2025

The Nontuberculous Mycobacterial Infection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Nontuberculous Mycobacterial Infection Market Size and Projected Growth Rate?
The market size for nontuberculous mycobacterial infection has experienced robust growth in the past few years. The market that was valued at $14.25 billion in 2024 is expected to expand to $15.11 billion in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors such as enhanced diagnostic procedures, an increasing elderly population, heightened awareness of cystic fibrosis, and use of immunosuppressive medications have contributed to the growth during the historic period.

The market size for nontuberculous mycobacterial infection is projected to witness hefty expansion in the coming years, elevating to $19.57 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. This growth during the forecasted period is largely due to the progress in antimicrobial drug development, enhanced understanding of ntm, advancements in genetic research as well as telehealth and remote monitoring. Some of the main trends projected for the forecast period comprise personalized treatment plans, regulatory emphasis, combination treatment strategies, and the utilization of digital health tools.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020

What Are the Major Segments in the Nontuberculous Mycobacterial Infection Market?
The nontuberculous mycobacterial infection market covered in this report is segmented -

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

What Are The Driving Nontuberculous Mycobacterial Infection Market Evolution?
The nontuberculous mycobacterial infection market is projected to experience significant growth due to the increasing incidence of chronic obstructive pulmonary disease (COPD). COPD, a long-term lung disease characterized by continuous and often progressive airflow restriction, tends to exacerbate nontuberculous mycobacterial (NTM) infections. NTM infections in COPD patients have been linked with a steeper drop in forced expiratory volume in one second (FEV1) and a higher rate of exacerbations. COPD can impair the immune system and harm lung tissue, which in turn creates a conducive environment for NTM bacteria to invade the lungs. A report from The Scottish Public Health Observatory (ScotPHO) in March 2023 showed that the incidence rate of COPD increased between 2021 and 2022, with male rates having risen from 83.2 to 97.6 per 100,000 persons and female rates from 72.6 to 97.3. Thus, the escalating incidence of COPD underpins the growth of the nontuberculous mycobacterial infection market. The rise in infectious diseases is another significant driver behind the expansion of the nontuberculous mycobacterial infection market. Infectious diseases, caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, can spread from one individual to another, leading to various symptoms and health issues. Any increase in infectious diseases, including those that can cause Nontuberculous Mycobacterial (NTM) infections, potentially fuels NTM infection market growth. This can be attributed to increased awareness around these infections, resulting in frequent diagnostic tests, early detection, elevated research and development initiatives for NTM treatments, and amplified demand for therapies confronting NTM pathogens due to a heightened medical focus on infectious diseases. For instance, data from the United Nations International Children's Emergency Fund (UNICEF) in November 2024 revealed that pneumonia, a leading infectious disease, claimed the lives of over 700,000 children every year, equivalent to roughly 2,000 children per day. Thus, rising infectious diseases incidence bolsters the growth of the nontuberculous mycobacterial infection market.

Which Firms Dominate The Nontuberculous Mycobacterial Infection Market Segments?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

What Trends Are Expected to Dominate the Nontuberculous Mycobacterial Infection Market in the Next 5 Years?
Predominant businesses in the nontuberculous mycobacterial infection market undertake new approval methods like fast track designation for drug sanction to maintain their market position. The Fast Track approval process by the FDA is specifically designed to speed up the development and evaluation of medications meant for serious diseases with unmet medical requirements. For example, in July 2022, the Food and Drug Administration, a federal entity in the United States, bestowed Fast Track Designation to NUZYRA for addressing nontuberculous mycobacterial (NTM) lung disease triggered by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic tailored to tackle severe bacterial infections, inclusive of those produced by resistant strains. This designation paves the way for expedited development and review procedures for the NUZYRA antibiotic for dealing with significant unmet medical requirements.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Which Is The Largest Region In The Nontuberculous Mycobacterial Infection Market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Nontuberculous Mycobacterial Infection Market?
2. What is the CAGR expected in the Nontuberculous Mycobacterial Infection Market?
3. What Are the Key Innovations Transforming the Nontuberculous Mycobacterial Infection Industry?
4. Which Region Is Leading the Nontuberculous Mycobacterial Infection Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.